Immatics N.V. is a clinical-stage biopharmaceutical company dedicated to developing highly specific T cell receptor (TCR)-based immunotherapies for cancer patients. The company operates primarily out of Tuebingen, Germany, and Houston, Texas. Immatics' core business model revolves around its proprietary target discovery platform, XPRESIDENT, which identifies true cancer targets (peptides presented by human leukocyte antigens) that are otherwise inaccessible on the cell surface.
The company's therapeutic pipeline is divided into two distinct modalities: Adoptive Cell Therapies (ACT) and TCR Bispecifics (TCER). The ACT approach involves engineering a patient's own T cells to express a cancer-specific TCR, while the TCER approach utilizes off-the-shelf, antibody-like biologic molecules that bind to both the tumor target and T cells to trigger an immune response. A key focus of its clinical pipeline is the precision targeting of PRAME, an antigen expressed in over 50 types of solid cancers, including melanoma and gynecologic cancers.
As a clinical-stage biotech, Immatics does not yet generate revenue from commercial product sales. Instead, its revenue is derived entirely from strategic collaboration and licensing agreements with major pharmaceutical companies, such as Bristol Myers Squibb and Moderna. These partnerships provide upfront payments, research funding, and potential milestone payments, which help fund the company's extensive research and development activities. Immatics' competitive position is anchored by its deep expertise in immunology, its robust target discovery capabilities, and its broad PRAME franchise.
